United Therapeutics (NASDAQ:UTHR) CEO Sells $3,926,212.60 in Stock

Key Points

• CEO Martine Rothblatt sold 7,580 United Therapeutics shares for approximately $3.93 million at an average price of $517.97, reducing her direct ownership by 2.27% to 326,363 shares.
• United Therapeutics won a Delaware patent ruling against Liquidia over Yutrepia, potentially limiting competition with its Tyvaso franchise in the PH-ILD market, though further legal and regulatory actions remain possible.
• The stock recently traded at $571.38, while analysts maintain a consensus “Moderate Buy” rating and an average price target of $621. The company’s latest quarter beat EPS expectations but missed revenue estimates, with sales down 1.9% year over year.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 7,580 shares of the firm's stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $517.97, for a total transaction of $3,926,212.60. Following the completion of the transaction, the chief executive officer directly owned 326,363 shares in the company, valued at $169,046,243.11. This represents a 2.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

United Therapeutics stock traded up $29.49 during trading hours on Thursday, hitting $571.38. The company had a trading volume of 1,691,487 shares, compared to its average volume of 538,503. The firm has a market cap of $24.51 billion, a P/E ratio of 20.44, a P/E/G ratio of 2.41 and a beta of 0.56. United Therapeutics Corporation has a 1 year low of $409.07 and a 1 year high of $609.35. The company has a 50-day moving average price of $509.19 and a two-hundred day moving average price of $539.39.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the company posted $6.41 earnings per share. The company's quarterly revenue was down 1.9% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 26.21 EPS for the current year.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: A federal court in Delaware ruled that Liquidia’s Yutrepia infringes two United Therapeutics patent claims covering inhaled treprostinil for PH-ILD. The court also rejected Liquidia’s arguments that the claims were invalid. United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
• Positive Sentiment: The ruling could limit Yutrepia’s ability to compete in the PH-ILD market. United Therapeutics said it believes the decision may support an order requiring the FDA to withdraw Yutrepia’s approval until labeling excluding the PH-ILD indication is authorized, potentially reducing competitive pressure on Tyvaso and future cash flows. UTHR Prevails in LQDA’s Yutrepia Patent Dispute
• Positive Sentiment: Investors interpreted the legal victory as improving the durability of United Therapeutics’ pulmonary-hypertension franchise. The move was also supported by previously announced shareholder returns, including an accelerated share repurchase under the company’s remaining $2.0 billion authorization. Why United Therapeutics Stock Is Up Today
• Neutral Sentiment: The court ruling is a major development, but Liquidia may continue pursuing legal and regulatory options, so the ultimate timing and scope of any restrictions on Yutrepia remain uncertain. United Therapeutics Won Its Patent War and Liquidia Collapsed
• Negative Sentiment: Recent insider-trading data shows substantial selling by executives, including CEO Martine Rothblatt. While the transactions may have been conducted under prearranged plans, the absence of insider purchases could temper investor confidence. United Therapeutics Insider Trading

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of United Therapeutics in a research report on Thursday. Royal Bank Of Canada dropped their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Finally, The Goldman Sachs Group started coverage on shares of United Therapeutics in a research note on Thursday, September 24th. They issued a "sell" rating and a $321.00 price objective for the company. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $621.00.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the business. Toth Financial Advisory Corp lifted its holdings in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock worth $27,000 after buying an additional 48 shares during the period. Fiduciary Financial Advisors purchased a new position in shares of United Therapeutics in the 2nd quarter valued at $30,000. Caitlin John LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at $37,000. International Assets Investment Management LLC raised its position in shares of United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 64 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. purchased a new stake in shares of United Therapeutics during the 2nd quarter worth $81,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.